Replies to post #125000 on Biotech Values

[mcbio]

In BMY’s all-oral cohort, there were 11 patients in all, 9 with genotype-1a and 2 with genotype-1b. Of the 9 genotype-1a patients, 2 had SVR12, 1 relapsed after completing treatment, 6 had viral breakthrough, and 2 never reached undetectable VL. Both of the genotype-1b patients had SVR12 (#msg-55118600, #msg-60946871). Thus, there were not enough data to be definitive; however, the patients with genotype-1b had better results than the patients with genotype-1a, so the data were at least consistent with what ACHN contends.

Very interesting. Thanks for the response.